Cara Therapeutics - Nach Absturz der Höhenflug?
Cara Therapeutics to Webcast Presentation at the 15th Annual Needham Healthcare Conference
SHELTON, Conn., April 05, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will present a company overview at the 15th Annual Needham Healthcare Conference on Tuesday, April 12, 2016, at 10:00 a.m. ET in New York City.
A live webcast of the presentation can be accessed under Events and Presentations in the News & Investors section of the Companys website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days.
Needham & Companys 15th Annual Healthcare Conference
April 12 - April 13, 2016
Needham & Companys 15th Annual Healthcare Conference is a high-impact forum for institutional investors and venture capital firms to hear the latest updates from senior management teams of both leading public and private companies in the Biotechnology, Specialty Pharmaceuticals, Medical Technology and Diagnostics sectors. One-on-one meetings will be scheduled based on company availability and investor interest. This conference is open to clients of Needham & Company, LLC only. For further information, please contact your Needham salesperson.
Gestern hoch auf 6,91$!
Mir macht cara bisher Spaß.
http://finviz.com/quote.ashx?t=CARA
im Moment so richtig Spass machen. Und beide haben noch riesen Potential. Und wenn ich bedenke, dass da noch so ein paar Aktien in meinem Depot nur noch auf einen Ten Bugger warten, na ja, da will ich mal zufrieden sein und vergesse, dass ich unterm Strich mit dem ganzen Depot tief in den roten Zahlen stecke. Weiter viel Spass euch allen!
Dr. Derek Chalmers, President and CEO, will present a company overview at the 15th Annual Needham Healthcare Conference on Tuesday, April 12, 2016, at 10:00 a.m. ET in New York City
Ich glaube zwar nicht, dass heute was zum FDA clin. hold bekanntgegeben wird, dennoch blicke ich mit gewisser Spannung nach New York heute nachmittag.
Der Cara-Kurs hatte die Woche ein kleines Minus von 3.36%.
Monats-Performance allerdings noch bei 26%
Seit dem 52-week-low liegen "wir" noch 55% im plus.
http://finviz.com/quote.ashx?t=CARA
Der Cara Kurs konnte über 6,8% zulegen und stieg bei hohem Volumen um 0,45 auf 7,06$.
Seit dem Tief Ende Februar bei 4,26$ stieg der Kurs mittlerweile 65%!
Und es ist noch viel viel viel Luft nach oben.
http://finviz.com/quote.ashx?t=CARA
http://finviz.com/quote.ashx?t=CARA
Gestern Schlusskurs 8,12$ !!!
Vor gut 6 Wochen lagen wir noch bei 4,26$.
Inzwischen über +90%.
Und es ist noch gaaaaanz viel Luft nach oben!
Optionen
| Boardmail an "Cobra7" |
Wertpapier: Cara Therapeutics Inc. |
Angehängte Grafik:
sc.png (verkleinert auf 60%)
sc.png (verkleinert auf 60%)
Optionen
| Boardmail an "Balu4u" |
Wertpapier: Cara Therapeutics Inc. |
Moderation
Zeitpunkt: 19.04.16 15:40
Aktionen: Löschung des Beitrages, Nutzer-Sperre für immer
Kommentar: Werbe-ID
Zeitpunkt: 19.04.16 15:40
Aktionen: Löschung des Beitrages, Nutzer-Sperre für immer
Kommentar: Werbe-ID
Erst ging es hoch auf 8,69$ (!), dann runter auf 7,73$ und wieder hoch bis zum Schlusskurs bei 8,22$.
Cara macht Spaß.
http://finviz.com/quote.ashx?t=CARA
Cara Therapeutics Announces Removal of FDA Clinical Hold on CLIN3001 Postoperative Pain Trial for I.V. CR845
April 20, 2016 07:00 ET | Source: Cara Therapeutics Inc.
Patient recruitment expected to resume in May
Study to evaluate two doses of I.V. CR845 versus placebo
SHELTON, Conn., April 20, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that it has received notice from the U.S. Food and Drug Administration (FDA) that it has removed the clinical hold on its adaptive Phase 3 trial of I.V. CR845 for postoperative pain.
The clinical hold was triggered by a protocol-specified stopping criterion, based on elevated serum sodium levels, that was met during the first phase of the study. A subsequent review of unblinded safety data from the first 90 patients dosed was completed by Cara, the studys Independent Data Monitoring Committee (IDMC), and the FDA.
The results of this safety data review confirmed that increases in serum sodium levels in CR845-treated patients beyond the normal range were dose-dependent and asymptomatic with the lowest frequency of events found in the 1 ug/kg I.V. CR845 group. Based on this safety review and an analysis of efficacy trends, the study will continue as a three-arm trial testing two doses of CR845 (1 ug/kg and 0.5 ug/kg) versus placebo.
"The Cara development team has worked diligently with the FDA to analyze patient data and conclude the Agencys review process in a timely manner," said Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer of Cara Therapeutics. "Our unblinded analysis of the initial cohort of patients has identified interim efficacy signals for pain, supplemental opioid use and opioid-related side effects that support our dose selections. We look forward to continuing patient recruitment next month and to providing further updates on our progress later this year.
About the CLIN3001 Trial
The CLIN3001 study is a multi-center, randomized, double-blind, placebo-controlled, parallel-group adaptive design Phase 3 trial with repeated doses of I.V. CR845 or placebo administered both prior to and following abdominal surgery in male and female patients. The trial is enrolling up to 450 patients undergoing either hysterectomy, prostatectomy, hemi-colectomy or ventral hernia repair at approximately 30 clinical sites within the U.S. Two dose levels of I.V. CR845 (1.0, and 0.5 ug/kg I.V.) are being compared to placebo. The primary efficacy measure is the Change in Pain Intensity over the 24-hour postoperative period (AUC-24) using the patient-reported Numeric Rating Scale (NRS) score collected at pre-specified time points through 24 hours. Postoperative nausea and vomiting (PONV) will be evaluated as a secondary efficacy measure. The impact of CR845 treatment on inflammatory biomarkers is also being explored.
About CR845
CR845 is a peripherally acting kappa opioid receptor agonist currently in development for the treatment of acute and chronic pain and pruritus. In multiple randomized, double-blind, placebo-controlled Phase 2 trials in patients undergoing laparoscopic hysterectomy or bunionectomy procedures, I.V. CR845 treatment resulted in statistically significant reductions in both pain intensity and opioid-related side effects. In more than 440 subjects dosed to date, I.V. CR845 was found to be well tolerated, without incurring the dysphoric and psychotomimetic side effects that have been reported with centrally acting (CNS-active) kappa opioid receptor agonists.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.
Forward-looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forward-looking statements include statements concerning the resumption of recruitment and dosing in the CLIN3001 clinical trial and the potential for I.V. CR845 to provide advantages in the treatment of postoperative pain at the dosing levels to be examined in the trial. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Cara Therapeutics' filings with the Securities and Exchange Commission, including the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2015 and its other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Cara Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
CORPORATE CONTACT:
Derek Chalmers, Ph.D., D.Sc.
President & CEO
Cara Therapeutics, Inc.
203-567-1500
MEDIA CONTACT:
Annie Starr
6 Degrees
973-415-8838
astarr@6degreespr.com
INVESTOR CONTACT:
Jesse Baumgartner
Stern Investor Relations, Inc.
212-362-1200
Jesse@sternir.com
Date : 04/20/2016 @ 8:30AM
Source : InvestorsHub NewsWire
Stock : Cara Therapeutics, Inc. (MM) (CARA)
Quote : 8.22 0.0 (0.00%) @ 8:35AM
§
Expansion of Legalized Cannabis Continues at a Torrid Pace in the U.S. and Globally For Leading Markets Worldwide
Expansion of Legalized Cannabis Continues at a Torrid Pace in the U.S. and Globally For Leading Markets Worldwide; Company Receives Purchase Order for Medical Marijuana Products
Coral Springs, FL -- April 20, 2016 -- InvestorsHub NewsWire -- Global opportunities are promising for legalized marijuana and cannabis sector as revenues continue to thrive behind increased federal & governmental research and development of latest products. Marijuana & Cannabis Companies with current operations and developments of importance in the markets today are New Colombia Resources, Inc. (OTC: NEWC), Cannabis Science, Inc. (OTC: CBIS), Cara Therapeutics (NASDAQ: CARA), Terra Tech Corp. (OTC: TRTC) and Cannabis Sativa Inc. (OTCBB: CBDS).
New Colombia Resources, Inc. (OTC: NEWC), a U.S. company with natural resource assets in Colombia, is pleased to announce that its subsidiary, Sannabis SAS, has received orders from an established pharmacy chain distributing natural products in southwest Colombia. Natural Pharmacy chain Salud Semillas, a leading distributor of natural products with an established customer base in southwest Colombia, has placed an initial purchase order and developed a marketing plan to generate strong sales. In addition to having stores in upscale malls and shopping centers they also sponsor a morning health talk radio show to discuss their featured products. The show targets an area of 350,000 people and attracts 25-35,000 listeners daily from 8-8:30 am. Salud Semillas marketing plan for Sannabis products includes radio talk shows, telemarketing group, internet sales, newspaper ads, and a direct to customer health magazine called Buena Vida which is distributed directly to thousands of customers homes monthly by Salud Semillas trained personnel in strategic neighborhoods. For more information on Salud Semillas visit www.saludsemillas.com. Their radio show is also broadcast in Spain, France, and Germany as well as online. To listen to the show tune into http://emisora.univalle.edu.co.
Read the full New Colombia Resources (NEWC) press release at: http://www.financialnewsmedia.com/profiles/newc.html
After 20 years of hard work developing high quality medical marijuana products in Colombia, Im pleased that we were finally able to establish a mainstream market, our orders are coming in droves, said Juan Pablo Guzman, Director of Sannabis in Colombia. Dr. Robert Melamede Ph.D., scientific advisor to Sannabis and New Colombia Resources, is now in Dubai as a guest speaker at the World Congress on Oncology and Radiology held from April 18-20. He presented at the Novel Approaches to Cancer Therapeutics session. Dr. Melamede is a world renowned expert of the bodys Endocannabinoid System and can easily educate world leaders on why cannabis cures and relieves. Dr. Melamede has firsthand knowledge of the effectiveness of Sannabis products in South America and is helping the company establish relationships and purchase orders with Middle Eastern countries. The cannabis awakening is spreading across the world. The scientific knowledge of the unique healing powers of this plant are now known by more and more people around the world. The truth can no longer be suppressed by ignorance, stated Dr. Robert Melamede, Scientific Advisor to Sannabis and New Colombia Resources.
In anticipation of having an approved export license, our approach to the international market is simple. You know cannabis cures but you dont want the hurdles of growing marijuana. Our region has grown the best medical strain for generations, we can grow and manufacture the highest quality 100% organic cannabis products for you at the most competitive cost possible. Colombian entrepreneurs are creating a new industry for the legal international medical cannabis and industrial hemp products market and were proud to be a part of it, commented John Campo President of New Colombia Resources Inc.
In other Cannabis/Legal Marijuana developments: Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabis-based medicines, is proud to extend its congratulations to the State of Pennsylvania as the 24th state to legalize cannabis for medical purposes. On Sunday, April 17, 2016, the Governor of Pennsylvania signed into law Senate Bill 3, legalizing medical cannabis consumption. Pennsylvania represents the 24th state to pass such legislation. The U.S. is nearly halfway to full medical legalization. As more states legalize medical cannabis, research and clinical trials can become simpler and less expensive to initiate and maintain.
Cara Therapeutics (NASDAQ: CARA) was mentioned in a recent article published by TheStreet.com as being one of three Marijuana-Related Stocks poised for strong growth. Cara Therapeutics develops chemical substances to treat various degrees of pain is Shelton, Conn. Cara is a clinical-stage biopharmaceutical company that develops and commercializes new drugs that alleviate pain by selectively targeting kappa opioid receptors, a human protein. While GW Pharmaceuticals (NASDAQ: GWPH) - another company mentioned in the article poised for strong growth - primarily treats pain through purified cannabis extracts that bind primarily to cannabinoid receptors in the brain (CB1), Cara boasts a more diverse and bigger portfolio of compounds focused on targeting immune cells (CB2) and unique opioid analgesics. Source: TheStreet.com
Terra Tech Corp. (OTC: TRTC) recently announced that its subsidiary, Edible Garden, a retail seller of locally grown hydroponic produce, herbs, and floral products, has signed an exclusive license agreement with Nutrasorb LLC, a spin-off of Rutgers University, to grow and commercialize nutritionally-enhanced lettuce varieties. Under the terms of the agreement, Edible Garden has the right to grow and sell Green and Red Super Lettuce across the North American and European continents as well as Australia. The produce will be high in vitamins A & C, magnesium, iron and potassium contents. It will also have high levels of fiber and chlorogenic acid. These nutritionally-enhanced, proprietary Green and Red Lettuces were developed by scientists at Rutgers University following years of intensive research.
Cannabis Sativa Inc. (OTCBB: CBDS) announced back in late February that HI Brands International Inc., a wholly owned subsidiary of Cannabis Sativa Inc., has entered into a trademark and licensing agreement with Trike Candy LLC, an Oregon Limited Liability Company to brand hi chocolate bars for the Oregon recreational marijuana market. Trike Candy is licensed to process marijuana infused products in the State of Oregon for sale in the recreational marijuana market.
FinancialNewsMedia.com is leading provider of third party publishing & news dissemination services. If you would like more information regarding our news coverage solutions, please visit financialnewsmedia.com for more details. Get an edge on the market with our Premium News Alerts that are FREE for a limited time at financialnewsmedia.com. Follow us on Facebook: facebook.com/financialnewsmedia and Twitter: twitter.com/FNMgroup.
DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNMG has been compensated one thousand nine hundred dollars for news coverage of the current press release issued by New Colombia Resources, Inc. by the company. FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.
meint Ihr, Eröffnung mit GAP-Up oder läuft auf Start $8,22 zurück ??
schau mir das mal heute genauer an, ob Nachkauf oder doch eher Verkauf..
hoffe die News treibt und der Chart vernachlässigt ;-)
Optionen
| Boardmail an "Cobra7" |
Wertpapier: Cara Therapeutics Inc. |
Tippe auf einen schnellen Anstieg über 10 Dollar.
Viele Gewinnmitnahmen, dann etwas runter.
Mittelfristig wird cara wieder über 15 Dollar steigen.
Laut privater Glaskugel. Alle Angaben ohne Gewähr.
Mein EK ist bei ca 4,50...
Gap ist zu, jetzt kann es weitergehen ;-))
Optionen
| Boardmail an "Cobra7" |
Wertpapier: Cara Therapeutics Inc. |
Heutiges Tief bei 8,20 (2 Cent unter Vortages-SK) ! Und das nach der FDA-News!
Krass.
Sehr enttäuschend. Aber mittelfristig geht´s hoch.
Wir dürften jetzt und heute noch sehr gute Einstiegskurse sehen .
siehe #42 ;-)
Optionen
| Boardmail an "Cobra7" |
Wertpapier: Cara Therapeutics Inc. |
Jetzt sieht´s schon etwas besser aus... mit 8,40 bis 8.48$
Egal, was heute noch passiert. CARA sehe ich bald wieder bei Kursen um die 15-17 Dollar.